The American Society for Reproductive Medicine’s committee opinion clearly states: “GnRH agonists may be offered to breast cancer patients to reduce the risk of premature ovarian insufficiency but should not be used in place of other fertility preservation alternatives” [14]. The gene discussed is GNRH1; the disease is breast carcinoma.